Abstract: To provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R0 represents any of a residue or a functional group derived from a cationic polymerization initiator; L represents a linker and L may not be present; n represents an integer of 1 or more; D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: An object is to provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R represents any of a residue derived from a polymerization initiator, or a functional group; A may not be present, and when present, A represents any of a low-molecular compound, a dye, a reporter molecule, a target-binding molecule, a polymer or D; L represents a linker and L may not be present; n1 represents an integer of 1 or more; and D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where R1, R2, and Y are as defined.

Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.

Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.

Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.

Abstract: An object is to provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R represents any of a residue derived from a polymerization initiator, or a functional group; A may not be present, and when present, A represents any of a low-molecular compound, a dye, a reporter molecule, a target-binding molecule, a polymer or D; L represents a linker and L may not be present; n1 represents an integer of 1 or more; and D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: To provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R0 represents any of a residue or a functional group derived from a cationic polymerization initiator; L represents a linker and L may not be present; n represents an integer of 1 or more; D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where Y, L1, R1 and R2 are as defined.

Abstract: A peptide that can be used as an imaging probe for GLP-1R is provided. In an embodiment, a polypeptide is represented by the following formula (3); (Sequence ID No. 3) Xaa1-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg- Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser- Ser-Gly-Ala-Pro-Pro-Pro-Ser (3) where Xaa1 represents an aspartic acid in which a —Y—X? group binds to an ?-amino group, X? includes a chelating site and a radioactive metal nuclide chelated by the chelating site, the chelating site being diethylenetriaminepentaacetic dianhydride (DTPA) or 1,4,7-triazacyclononnane-N,N?,N?-triacetic acid (NOTA), and Y represents a linker including a group selected from the group consisting of —CH2—(C6H4)—, —NH—C(?S)—, —NH—(CH2)5—C(?O)—, and a combination thereof.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: [Problem] To provide a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye in a blood component and emit fluorescence in a tumor or an inflamed site to be imaged).

Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.

Abstract: Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where R1, R2, and Y are as defined.

Abstract: Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where Y, L1, R1 and R2 are as defined.

Abstract: The present invention provides a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye during nanoparticle preparation, and emit fluorescence during imaging). A switching fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a cyanine compound represented by the formula (I): and two or more molecules of the fluorescent dye are encapsulated in the single molecular assembly.

Abstract: A new peptide derivative is provided.